The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Leveraging big data to transform target selection and drug discovery
Open accessAbstract
The advances of genomics, sequencing, and high throughput technologies have led to the creation of large volumes of diverse datasets for drug discovery. Analyzing these datasets to better understand disease and discover new drugs is becoming more common. Recent open data initiatives in basic and clinical research have dramatically increased the types of data available to the public. The past few years have witnessed successful use of big data in many sectors across the whole drug discovery pipeline. In this review, we will highlight the state of the art in leveraging big data to identify new targets, drug indications, and drug response biomarkers in this era of precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
A New Initiative on Precision Medicine
Collins, F. S., & Varmus, H. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500523 · Cited by 5,202
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Genetics of rheumatoid arthritis contributes to biology and drug discovery
the RACI consortium, Okada, Y., the GARNET consortium, Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., Kochi, Y., Ohmura, K., et al. (2014) · Nature · doi:10.1038/nature12873 · Cited by 2,310
Cited by
Metascape provides a biologist-oriented resource for the analysis of systems-level datasets
Zhou, Y., Zhou, B., Pache, L., Chang, M., Khodabakhshi, A. H., Tanaseichuk, O., Benner, C., & Chanda, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-09234-6 · Cited by 14,611
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Next-Generation Machine Learning for Biological Networks
Camacho, D. M., Collins, K. M., Powers, R. K., Costello, J. C., & Collins, J. J. (2018) · Cell · doi:10.1016/j.cell.2018.05.015 · Cited by 976
Li, Y. H., Yu, C. Y., Li, X. X., Zhang, P., Tang, J., Yang, Q., Fu, T., Zhang, X., Cui, X., Tu, G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1076 · Cited by 523
Artificial Intelligence and Personalized Medicine
Schork, N. J. (2019) · Cancer Treatment and Research · doi:10.1007/978-3-030-16391-4_11 · Cited by 488
Computational approaches in target identification and drug discovery
Katsila, T., Spyroulias, G. A., Patrinos, G. P., & Matsoukas, M.-T. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.04.004 · Cited by 390
Computational/in silico methods in drug target and lead prediction
Agamah, F. E., Mazandu, G. K., Hassan, R., Bope, C. D., Thomford, N. E., Ghansah, A., & Chimusa, E. R. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbz103 · Cited by 328
Big data in IBD: a look into the future
Olivera, P., Danese, S., Jay, N., Natoli, G., & Peyrin-Biroulet, L. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0102-5 · Cited by 151
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0240-9 · Cited by 154
Self-citationDesign of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
Taubes, A., Nova, P., Zalocusky, K. A., Kosti, I., Bicak, M., Zilberter, M. Y., Hao, Y., Yoon, S. Y., Oskotsky, T., Pineda, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00122-7 · Cited by 118
Self-citationZeng, B., Glicksberg, B. S., Newbury, P., Chekalin, E., Xing, J., Liu, K., Wen, A., Chow, C., & Chen, B. (2021) · Nature Protocols · doi:10.1038/s41596-020-00430-z · Cited by 48
Self-citation
Metadata
- Authors
- Chen, B., & Butte, A.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2016-02-17
- Volume
- 99
- Issue
- 3
- Pages
- 285-297
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2191030086
- Cited by
- 160
- References
- 22
- FWCI
- 17.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.